GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Operating Margin %

ME Therapeutics Holding (XCNQ:METX) Operating Margin % : 0.00% (As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. ME Therapeutics Holding's Operating Income for the three months ended in Feb. 2024 was C$-0.15 Mil. ME Therapeutics Holding's Revenue for the three months ended in Feb. 2024 was C$0.00 Mil. Therefore, ME Therapeutics Holding's Operating Margin % for the quarter that ended in Feb. 2024 was 0.00%.

The historical rank and industry rank for ME Therapeutics Holding's Operating Margin % or its related term are showing as below:


XCNQ:METX's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -155.93
* Ranked among companies with meaningful Operating Margin % only.

ME Therapeutics Holding's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

ME Therapeutics Holding's Operating Income for the three months ended in Feb. 2024 was C$-0.15 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Feb. 2024 was C$-1.40 Mil.


ME Therapeutics Holding Operating Margin % Historical Data

The historical data trend for ME Therapeutics Holding's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Operating Margin % Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
Operating Margin %
- -

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
Operating Margin % Get a 7-Day Free Trial - - - - -

Competitive Comparison of ME Therapeutics Holding's Operating Margin %

For the Biotechnology subindustry, ME Therapeutics Holding's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ME Therapeutics Holding's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's Operating Margin % distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's Operating Margin % falls into.



ME Therapeutics Holding Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

ME Therapeutics Holding's Operating Margin % for the fiscal year that ended in Aug. 2023 is calculated as

Operating Margin %=Operating Income (A: Aug. 2023 ) / Revenue (A: Aug. 2023 )
=-0.977 / 0
= %

ME Therapeutics Holding's Operating Margin % for the quarter that ended in Feb. 2024 is calculated as

Operating Margin %=Operating Income (Q: Feb. 2024 ) / Revenue (Q: Feb. 2024 )
=-0.145 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ME Therapeutics Holding  (XCNQ:METX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


ME Therapeutics Holding Operating Margin % Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ME Therapeutics Holding (XCNQ:METX) Business Description

Comparable Companies
Traded in Other Exchanges
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines